Literature DB >> 29696436

Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.

Dimitrios A Pappas1,2, Fredrik Nyberg3,4, Joel M Kremer5, Kathy Lampl6, George W Reed7,8, Laura Horne9, Meilien Ho10, Alina Onofrei7, Anand N Malaviya11, Oscar L Rillo12, Sebastiao C Radominski13, Janos Gal14, Allan Gibofsky15, Tatiana V Popkova16, Leda Laurindo17, Eduardo M Kerzberg18, Roman Zahora19, Bernado A Pons-Estel20, Jeffrey R Curtis21, Daniel E Furst22, Jeffrey D Greenberg7,23.   

Abstract

To compare the prevalence of cardiovascular disease (CVD) and major CVD risk factors among rheumatoid arthritis (RA) patients enrolled in a large US and multinational registry. We compared CVD and CVD risk factor prevalence from 11 countries enrolled in the CORRONA US and CORRONA International registries; patients from the 10 ex-US participating countries were grouped by region (Eastern Europe, Latin America, and India). Unadjusted summary data were presented for demographics and disease characteristics; comparisons for prevalence of CVD risk factors and CVD were age/gender standardized to the age/gender distribution of the US enrolled patients. Overall, 25,987 patients were included in this analysis. Compared to patients from the ex-US regions, US participants had longer disease duration and lower disease activity, yet were more likely to receive a biologic agent. Additionally, CORRONA US participants had the highest body mass index (BMI). Enrolled patients in India had the lowest BMI, were more rarely smokers, and had a low prevalence of hyperlipidemia, hypertension, and prior CVD compared to the US and other ex-US regions. Participants from Eastern Europe had a higher prevalence of hypertension and hyperlipidemia and highest prevalence of all manifestations of CVD. Differences in the prevalence of both CVD and major CVD risk factors were observed across the four regions investigated. Observed differences may be influenced by variations in both non-modifiable/modifiable characteristics of patient populations, and may contribute to heterogeneity on the observed safety of investigational and approved therapies in studies involving RA patients from different origins.

Entities:  

Keywords:  Cardiovascular disease; Cardiovascular risk factors; Epidemiology; Prevalence; Registry; Rheumatoid arthritis

Mesh:

Year:  2018        PMID: 29696436     DOI: 10.1007/s10067-018-4113-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  26 in total

Review 1.  Epidemiology of uncontrolled hypertension in the United States.

Authors:  Thomas J Wang; Ramachandran S Vasan
Journal:  Circulation       Date:  2005-09-13       Impact factor: 29.690

Review 2.  The CORRONA database.

Authors:  Joel M Kremer
Journal:  Autoimmun Rev       Date:  2005-08-30       Impact factor: 9.754

3.  Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis.

Authors:  A Young; G Koduri; M Batley; E Kulinskaya; A Gough; S Norton; J Dixey
Journal:  Rheumatology (Oxford)       Date:  2006-08-14       Impact factor: 7.580

4.  Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992.

Authors:  A G Kvalvik; M A Jones; D P Symmons
Journal:  Scand J Rheumatol       Date:  2000       Impact factor: 3.641

5.  Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset.

Authors:  S Wållberg-Jonsson; H Johansson; M L Ohman; S Rantapää-Dahlqvist
Journal:  J Rheumatol       Date:  1999-12       Impact factor: 4.666

6.  Deaths from arthritis and other rheumatic conditions, United States, 1979-1998.

Authors:  Jeffrey J Sacks; Charles G Helmick; Gary Langmaid
Journal:  J Rheumatol       Date:  2004-09       Impact factor: 4.666

7.  Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study.

Authors:  Mike J L Peters; Vokko P van Halm; Alexandre E Voskuyl; Yvo M Smulders; Maarten Boers; Willem F Lems; Marjolein Visser; Coen D A Stehouwer; Jacqueline M Dekker; Giel Nijpels; Rob Heine; Ben A C Dijkmans; Michael T Nurmohamed
Journal:  Arthritis Rheum       Date:  2009-11-15

8.  The widening mortality gap between rheumatoid arthritis patients and the general population.

Authors:  Angel Gonzalez; Hilal Maradit Kremers; Cynthia S Crowson; Paulo J Nicola; John M Davis; Terry M Therneau; Veronique L Roger; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2007-11

Review 9.  Cardiovascular morbidity and mortality in rheumatoid arthritis.

Authors:  Sherine E Gabriel
Journal:  Am J Med       Date:  2008-10       Impact factor: 4.965

10.  Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO).

Authors:  J Jaime Miranda; Victor M Herrera; Julio A Chirinos; Luis F Gómez; Pablo Perel; Rafael Pichardo; Angel González; José R Sánchez; Catterina Ferreccio; Ximena Aguilera; Eglé Silva; Myriam Oróstegui; Josefina Medina-Lezama; Cynthia M Pérez; Erick Suárez; Ana P Ortiz; Luis Rosero; Noberto Schapochnik; Zulma Ortiz; Daniel Ferrante; Juan P Casas; Leonelo E Bautista
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

View more
  5 in total

Review 1.  Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes.

Authors:  Giulia Frazzei; Ronald F van Vollenhoven; Brigit A de Jong; Sarah E Siegelaar; Dirkjan van Schaardenburg
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

2.  Patient Perception of Cardiovascular Risk in Rheumatoid Arthritis.

Authors:  Shubhasree Banerjee; Michael D George; Sukhraj Singh; Jennifer Tchervenkov; Amber Van Heusen; Mohamed Tageldin; Mark Riley; Muhammad Saad Shaukat; Nicholas Demenagas; Kevin Le; Tiffany Oliveira; Sooyeon Kwon; Paul Feustel; Joel M Kremer
Journal:  ACR Open Rheumatol       Date:  2020-04-20

Review 3.  Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.

Authors:  Sakir Ahmed; Armen Yuri Gasparyan; Olena Zimba
Journal:  Rheumatol Int       Date:  2021-01-03       Impact factor: 3.580

4.  Prevalence of Hypertension and Its Associated Risk Factors Among Patients with Rheumatoid Arthritis in the Kingdom of Saudi Arabia.

Authors:  Abdullah K Al-Ahmari
Journal:  Int J Gen Med       Date:  2022-08-08

5.  Incident arterial vascular events in a cohort of Puerto Ricans with rheumatoid arthritis.

Authors:  Ariana González-Meléndez; Ruth M Fred-Jiménez; Mariangelí Arroyo-Ávila; Leyda Díaz-Correa; Naydi Pérez-Ríos; Noelia Rodríguez; Grissel Ríos; Luis M Vilá
Journal:  SAGE Open Med       Date:  2020-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.